Click Here for 5% Off Your First Aladdin Purchase!

RE 201 - 98%, high purity , Type-1 angiotensin II receptor antagonist, CAS No.254740-64-2, Type-1 angiotensin II receptor antagonist

  • Moligand™
  • ≥98%
Item Number
R340645
Grouped product items
SKUSizeAvailabilityPrice Qty
R340645-25mg
25mg
In stock
$489.90
R340645-50mg
50mg
In stock
$815.90
R340645-100mg
100mg
In stock
$1,360.90
R340645-250mg
250mg
In stock
$3,062.90

Basic Description

Synonymssparsentan|254740-64-2|Sparsentan (RE-021)|RE-021|retrophin|PS433540|Sparsentan [USAN]|FILSPARI|PS-433540|UNII-9242RO5URM|DARA|9242RO5URM|PS 33540|CHEMBL539423|4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(e
Specifications & Purity98%
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeANTAGONIST
Mechanism of actionType-1 angiotensin II receptor antagonist

Product Properties

ALogP5

Associated Targets

AGTR1 Tclin Type-1 angiotensin II receptor 3 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

EDNRA Tclin Endothelin-1 receptor 3 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

IUPAC Name 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide
INCHI InChI=1S/C32H40N4O5S/c1-5-7-14-29-33-32(17-10-11-18-32)31(37)36(29)20-24-15-16-26(25(19-24)21-40-6-2)27-12-8-9-13-28(27)42(38,39)35-30-22(3)23(4)41-34-30/h8-9,12-13,15-16,19H,5-7,10-11,14,17-18,20-21H2,1-4H3,(H,34,35)
InChi Key WRFHGDPIDHPWIQ-UHFFFAOYSA-N
Canonical SMILES CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC(=C(C=C3)C4=CC=CC=C4S(=O)(=O)NC5=NOC(=C5C)C)COCC
Isomeric SMILES CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC(=C(C=C3)C4=CC=CC=C4S(=O)(=O)NC5=NOC(=C5C)C)COCC
PubChem CID 10257882
Molecular Weight 592.75

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

4 results found

Lot NumberCertificate TypeDateItem
K2223528Certificate of AnalysisJul 22, 2022 R340645
K2223531Certificate of AnalysisJul 22, 2022 R340645
K2223532Certificate of AnalysisJul 22, 2022 R340645
K2223533Certificate of AnalysisJul 22, 2022 R340645

Related Documents

References

1. Murugesan N, Gu Z, Fadnis L, Tellew JE, Baska RA, Yang Y, Beyer SM, Monshizadegan H, Dickinson KE, Valentine MT et al..  (2005)  Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics..  J Med Chem,  48  (1): (171-9).  [PMID:15634011]
2. Morphy R, Rankovic Z.  (2005)  Designed multiple ligands. An emerging drug discovery paradigm..  J Med Chem,  48  (21): (6523-43).  [PMID:16220969]
3. D'Agati VD, Kaskel FJ, Falk RJ.  (2011)  Focal segmental glomerulosclerosis..  N Engl J Med,  365  (25): (2398-411).  [PMID:22187987]
4. Hodson EM, Sinha A, Cooper TE.  (2022)  Interventions for focal segmental glomerulosclerosis in adults..  Cochrane Database Syst Rev,  (2): (CD003233).  [PMID:35224732]

Solution Calculators